Axinn Represents Alvogen Before FTC in Connection with Divested Products from Pfizer and Hospira

April 21, 2026

Informa 35th Annual Advanced EU London Conference

On April 21, Axinn partner Katrina Rouse will speak on the "Defence Readiness Omnibus: Competition Law Considerations" panel at Informa's Advanced EU London Conference, being held April 21-22.

Speaking Engagement

Antitrust

April 13, 2026

AHLA Health Care Transactions Program 2026

Axinn is proud to sponsor the American Health Law Association’s Health Care Transactions Program, being held April 13-15 in Nashville, Tennessee.

Sponsorship

Antitrust

March 23, 2026

IPWatchdog Sixth Annual Live Conference

On March 23, Axinn partner Brian Johnson will speak on the "Winning ITC Strategy: A Practitioner’s Guide to 337 Litigation" panel at IPWatchdog's sixth annual Live Conference, being held March 22-24 in Arlington, Virginia.

Speaking Engagement

Intellectual Property

March 19, 2026

The DOJ's Whistleblower Program and Leniency

The DOJ Antitrust Division's new Whistleblower Rewards Program could have negative unintended consequences for the leniency program and...

Axinn Viewpoints

Antitrust

March 13, 2026

Squires Again Broadens Discretion for Post-Grant Proceedings

On Wednesday, March 11, 2026, United States Patent and Trademark Office (USPTO) Director John Squires issued a memorandum[1] announcing...

Axinn Viewpoints

Intellectual Property

March 11, 2026

ABA White Collar Crime Institute 2026

On March 11, Axinn partner Jacklin Chou Lem will moderate the "Trends and Recent Developments in Criminal Antitrust Enforcement" panel at the American Bar Association's White Collar Crime Institute, being held March 10-13 in San Diego.

Speaking Engagement

March 10, 2026

Back to the Well: FDA’s Draft Guidance on New Clinical Investigation Exclusivity

Introduction FDA recently published a new draft Guidance for Industry titled “New Clinical Investigation Exclusivity (3-Year Exclusivity)...

Axinn Viewpoints

Intellectual Property

March 9, 2026

Mother, May I? The Use of Prior Approval Requirements in Merger Settlements

Federal enforcers continue to refine the tools they use in merger enforcement—including the use of prior approval provisions, once considered an extraordinary remedy in merger settlements. In this episode, Managing Partner Jeny Maier joins co-host Anora Wang in conversation with former FTC policy leader Bilal Sayyed to examine how these provisions have evolved across administrations and what their changing use reveals about current agency policy.

Podcast

Antitrust

March 9, 2026

The Curtain Rises Again on FTC Act Section 5

Section 5 of the FTC Act prohibits “unfair methods of competition.” Section 5, which has been endorsed by many as necessary to fill gaps...

Axinn Viewpoints

March 6, 2026

Jeny Maier Named Finalist for Managing Partner of the Year in 2026 Women, Influence & Power in Law Awards

Axinn Managing Partner Jeny Maier has been named a finalist for Managing Partner of the Year in the 2026 Women, Influence & Power in Law (WIPL) Awards, presented by Corporate Counsel. The WIPL Awards recognize outstanding in-house and law firm attorneys who are advancing the empowerment and leadership of women across the legal profession.

Awards & Recognitions

March 5, 2026

DOJ Serves Up a Statement of Interest with a Side of Fries

Last Friday, the DOJ filed a Statement of Interest in In Re Frozen Potato Products Antitrust Litigation, a multidistrict price fixing...

Axinn Viewpoints

Antitrust

March 3, 2026

GCR Live Cartels: 2026

On March 3, Axinn partner Dan Oakes will speak on the "A New Kind of Payday: Whistleblower Program Rewards" panel at Global Competition Review's Cartels Conference in Washington, DC.

Speaking Engagement

Antitrust

Axinn Represents Alvogen Before FTC in Connection with Divested Products from Pfizer and Hospira

Related People

Related Services

Related Locations

Featured Insights

Featured Insights